share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Jan 25 09:09
Summary by Moomoo AI
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced a registered direct offering to institutional investors, with the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS, aiming to raise $8 million in gross proceeds. The offering, expected to close on January 29, 2024, also includes the issuance of unregistered warrants to purchase an equivalent number of ADSs, exercisable at $1.00 per ADS and valid for five years. H.C. Wainwright & Co. is the exclusive placement agent for this offering. The net proceeds are intended for general corporate purposes, including working capital, acquisitions, and research and development. The ADSs are offered under a shelf registration statement on Form F-3, effective since August 9, 2021. The warrants, along with the ADSs underlying them, are issued in a private placement and are not registered under the Securities Act, thus are subject to specific conditions for sale in the United States.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more